RECURRENT GLIOMA

This study tests whether the drug olaparib can shrink or slow the growth of advanced solid tumors that have IDH1 or IDH2 gene mutations, including certain brain tumors (gliomas) and bile duct cancers (cholangiocarcinoma). About 89 adults whose cancer has spread or not responded t…

This study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…

This study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…

This early-phase trial tests whether specially engineered immune cells (T cells) can safely target and kill recurrent malignant glioma, an aggressive brain cancer. About 29 patients will receive these cells to find the best dose and check for side effects. The goal is to control …

This study tests a new type of MRI that looks at sodium and other signals in the brain to get a clearer picture of tumors. It includes healthy volunteers and people with brain tumors (glioma) that are new or have returned. The goal is to improve how doctors detect, understand, an…

This study was designed to see if a diet low in two amino acids (cysteine and methionine) could change the body's chemistry in people with recurrent brain tumors. It planned to enroll up to 30 participants and compare the special diet to a regular diet before standard treatments …

This early-stage trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation so researchers can measure how much drug reaches the tumor and how it affects cancer cells. The goal is to ga…

This study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…